IMMUNOVANT INC. - COMMON STOCK

Immunovant Appoints Mark Levine as Chief Legal Officer

25 янв 2022 08:30:00 Источник Nasdaq GlobeNewswire

Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference

07 янв 2022 14:07:31 Источник Nasdaq GlobeNewswire

Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

30 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

12 ноя 2021 12:18:05 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended September 30, 2021

05 ноя 2021 07:30:00 Источник Nasdaq GlobeNewswire

Immunovant to Participate in Roivant R&D Day 2021

27 сен 2021 08:00:00 Источник Nasdaq GlobeNewswire

Immunovant Appoints Renee Barnett as Chief Financial Officer

15 сен 2021 07:00:01 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended June 30, 2021

09 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire

Immunovant to Report Financial Results for Quarter Ended June 30, 2021

06 авг 2021 16:22:27 Источник Nasdaq GlobeNewswire

Immunovant Receives $200 Million Strategic Investment from Roivant Sciences

02 авг 2021 07:30:00 Источник Nasdaq GlobeNewswire

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

01 июн 2021 07:31:18 Источник Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020

16 фев 2021 08:00:04 Источник Nasdaq GlobeNewswire

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

02 фев 2021 06:30:00 Источник Nasdaq GlobeNewswire

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

12 янв 2021 17:00:00 Источник Nasdaq GlobeNewswire